Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Prestige Consumer Healthcare Inc. (NYSE:PBH) has received a consensus rating of “Moderate Buy” from the four analysts that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $85.25.

A number of analysts recently commented on PBH shares. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a research report on Monday, December 9th. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. DA Davidson reiterated a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Tuesday. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th.

Prestige Consumer Healthcare Stock Performance

NYSE:PBH opened at $74.45 on Friday. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $3.68 billion, a P/E ratio of 18.11, a price-to-earnings-growth ratio of 2.32 and a beta of 0.51. The firm has a 50 day moving average of $80.56 and a 200-day moving average of $74.17. Prestige Consumer Healthcare has a 1 year low of $58.22 and a 1 year high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.09. The business had revenue of $283.79 million during the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. Prestige Consumer Healthcare’s revenue for the quarter was down .9% compared to the same quarter last year. During the same quarter last year, the business posted $1.07 earnings per share. As a group, sell-side analysts anticipate that Prestige Consumer Healthcare will post 4.44 EPS for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 9,885 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total transaction of $810,273.45. Following the completion of the transaction, the senior vice president now directly owns 18,835 shares in the company, valued at $1,543,904.95. This represents a 34.42 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Ronald M. Lombardi sold 10,875 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the sale, the chief executive officer now owns 320,952 shares of the company’s stock, valued at $26,510,635.20. This trade represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock worth $3,187,300 in the last three months. Insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several hedge funds have recently bought and sold shares of the company. Ariel Investments LLC lifted its stake in Prestige Consumer Healthcare by 10.7% in the 2nd quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock valued at $195,204,000 after purchasing an additional 274,212 shares during the last quarter. Victory Capital Management Inc. lifted its stake in Prestige Consumer Healthcare by 9.0% in the 2nd quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock valued at $142,827,000 after purchasing an additional 171,357 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Prestige Consumer Healthcare by 19.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock valued at $113,570,000 after acquiring an additional 255,045 shares during the period. Geode Capital Management LLC raised its holdings in Prestige Consumer Healthcare by 4.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock valued at $95,678,000 after acquiring an additional 50,961 shares during the period. Finally, Congress Asset Management Co. raised its holdings in Prestige Consumer Healthcare by 7.8% in the 3rd quarter. Congress Asset Management Co. now owns 865,123 shares of the company’s stock valued at $62,375,000 after acquiring an additional 62,411 shares during the period. 99.95% of the stock is currently owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.